UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000018074
Receipt number R000020585
Scientific Title Evaluation of anthithrombin III therapeutic effect by frequency of administration in sepsis-associated disseminated intravascular coagulation
Date of disclosure of the study information 2015/06/24
Last modified on 2019/10/16 12:14:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of anthithrombin III therapeutic effect by frequency of
administration in sepsis-associated disseminated intravascular coagulation

Acronym

Evaluation of anthithrombin III therapeutic effect in sepsis

Scientific Title

Evaluation of anthithrombin III therapeutic effect by frequency of
administration in sepsis-associated disseminated intravascular coagulation

Scientific Title:Acronym

Evaluation of anthithrombin III therapeutic effect in sepsis

Region

Japan


Condition

Condition

Sepsis-associated disseminated intravascular coagulation

Classification by specialty

Intensive care medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate administration frequency for anti-thrombin III in disseminated intravascular coagulation

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The period of improving DIC.

Key secondary outcomes

Improvment of coagurative and inflammatory marker


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Dose comparison

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

1500U of AT was administered to the patients once a day

Interventions/Control_2

500U of AT was administered to the patients three times a day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The patient of sepsis-associated disseminated intravascular coagulation which was indicated under 70% of AT III activity.

Key exclusion criteria

Age: under 20 years old

Hematopoietic malignancy such as lykemia

Patient under the anticoagulan treatment such as heparin or warfarin

Liver cirrhosis (Child-Pugh score C)

The patient will die within a few days regardless of treatment.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ryu Yasuda

Organization

Gifu University Hospital

Division name

Advanced Critical Care Center

Zip code


Address

1-1 Yanagido, Gifu Japan

TEL

058-230-6448

Email

yasuryu@gifu-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ryu Yasuda

Organization

Gifu University Hospital

Division name

Advanced Critical Care Center

Zip code


Address

1-1 Yanagido, Gifu Japan

TEL

058-230-6448

Homepage URL


Email

yasuryu@gifu-u.ac.jp


Sponsor or person

Institute

Gifu University Hospital

Institute

Department

Personal name



Funding Source

Organization

CSL Behring

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 06 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2015 Year 06 Month 08 Day

Date of IRB

2015 Year 06 Month 15 Day

Anticipated trial start date

2015 Year 06 Month 15 Day

Last follow-up date

2019 Year 10 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 06 Month 24 Day

Last modified on

2019 Year 10 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020585


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name